{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:41:43Z","timestamp":1792431703142,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"National Institute on Drug Abuse Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA020024"],"award-info":[{"award-number":["UG1DA020024"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.cct.2025.107954","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T22:47:22Z","timestamp":1747003642000},"page":"107954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Randomized, placebo-controlled trial of injectable extended-release naltrexone and injectable extended-release buprenorphine for cocaine use disorder (CURB-2): Study rationale and design"],"prefix":"10.1016","volume":"154","author":[{"given":"Madhukar H.","family":"Trivedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah M.","family":"Kalmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Carmody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Chongsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udi E.","family":"Ghitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish K.","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn L.","family":"Mayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Casey-Willingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangita","family":"Sethuram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise N.","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Monastirsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Shoptaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2025.107954_bb0005","unstructured":"U.S. Overdose Deaths In 2021 Increased Half as Much as in 2020 \u2013 But Are Still Up 15%, 2022. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2022\/202205.htm. (Accessed 10\/05\/2023 2023)."},{"key":"10.1016\/j.cct.2025.107954_bb0010","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health","author":"SAMHSA","year":"2024"},{"issue":"12","key":"10.1016\/j.cct.2025.107954_bb0015","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1007\/s11606-019-05074-8","article-title":"Pharmacotherapy for cocaine use disorder-a systematic review and Meta-analysis","volume":"34","author":"Chan","year":"2019","journal-title":"J. Gen. Intern. Med."},{"issue":"3","key":"10.1016\/j.cct.2025.107954_bb0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/pr.115.011668","article-title":"Evaluation of the \u201cpipeline\u201d for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research","volume":"68","author":"Czoty","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.cct.2025.107954_bb0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/adb.12627","article-title":"Drug-induced dysphoria is enhanced following prolonged cocaine abstinence and dynamically tracked by nucleus accumbens neurons","volume":"24","author":"Haake","year":"2019","journal-title":"Addict. Biol."},{"issue":"15","key":"10.1016\/j.cct.2025.107954_bb0030","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00213-017-4647-0","article-title":"Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats","volume":"234","author":"Valenza","year":"2017","journal-title":"Psychopharmacology"},{"issue":"Pt B","key":"10.1016\/j.cct.2025.107954_bb0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.neuropharm.2013.04.025","article-title":"When a good taste turns bad: neural mechanisms underlying the emergence of negative affect and associated natural reward devaluation by cocaine","volume":"76","author":"Carelli","year":"2014","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.cct.2025.107954_bb0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"14","key":"10.1016\/j.cct.2025.107954_bb0045","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1111\/bph.16034","article-title":"The amygdala-ventral pallidum pathway contributes to a hypodopaminergic state in the ventral tegmental area during protracted abstinence from chronic cocaine","volume":"180","author":"Salin","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cct.2025.107954_bb0050","first-page":"466","article-title":"Glutamatergic synaptic plasticity in the mesocorticolimbic system in addiction","volume":"8","author":"van Huijstee","year":"2014","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.cct.2025.107954_bb0055","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12848","article-title":"Cocaine and chronic stress exposure produce an additive increase in neuronal activity in the basolateral amygdala","volume":"26","author":"Munshi","year":"2021","journal-title":"Addict. Biol."},{"issue":"13","key":"10.1016\/j.cct.2025.107954_bb0060","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1523\/JNEUROSCI.3667-06.2007","article-title":"Cocaine-associated stimuli increase cocaine seeking and activate accumbens core neurons after abstinence","volume":"27","author":"Hollander","year":"2007","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.cct.2025.107954_bb0065","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1046\/j.1460-9568.2003.02636.x","article-title":"Temporal upregulation of prodynorphin mRNA in the primate striatum after cocaine self-administration","volume":"17","author":"Fagergren","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.cct.2025.107954_bb0070","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.neuropharm.2016.01.004","article-title":"Strain and cocaine-induced differential opioid gene expression may predispose Lewis but not Fischer rats to escalate cocaine self-administration","volume":"105","author":"Valenza","year":"2016","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.cct.2025.107954_bb0075","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.neuron.2015.08.019","article-title":"Distinct subpopulations of nucleus Accumbens Dynorphin neurons drive aversion and reward","volume":"87","author":"Al-Hasani","year":"2015","journal-title":"Neuron"},{"issue":"13","key":"10.1016\/j.cct.2025.107954_bb0080","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1038\/npp.2014.157","article-title":"Kappa opioid receptor activation potentiates the cocaine-induced increase in evoked dopamine release recorded in vivo in the mouse nucleus accumbens","volume":"39","author":"Ehrich","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.cct.2025.107954_bb0085","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1523\/JNEUROSCI.1978-13.2015","article-title":"\u039a opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake","volume":"35","author":"Whitfield","year":"2015","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.cct.2025.107954_bb0090","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/add.13375","article-title":"Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the cocaine use reduction with buprenorphine (CURB) study","volume":"111","author":"Ling","year":"2016","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.cct.2025.107954_bb0095","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/0269881106060835","article-title":"Naltrexone and buprenorphine combination in the treatment of opioid dependence","volume":"20","author":"Gerra","year":"2006","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.cct.2025.107954_bb0100","series-title":"2015 Annual Meeting of the College on Problems of Drug Dependence, Drug and Alcohol Dependence, United States","first-page":"e233","article-title":"The cocaine use reduction with buprenorphine study: cocaine use findings","author":"Walter","year":"2015"},{"issue":"1","key":"10.1016\/j.cct.2025.107954_bb0105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/JCP.0000000000000434","article-title":"Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder","volume":"36","author":"Nasser","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.cct.2025.107954_bb0110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1360-0443.1988.tb00485.x","article-title":"Reliability of a timeline method: assessing normal drinkers\u2019 reports of recent drinking and a comparative evaluation across several populations","volume":"83","author":"Sobell","year":"1988","journal-title":"Br. J. Addict."},{"issue":"1","key":"10.1016\/j.cct.2025.107954_bb0115","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1037\/a0030992","article-title":"Reliability of the timeline followback for cocaine, cannabis, and cigarette use","volume":"28","author":"Robinson","year":"2014","journal-title":"Psychol. Addict. Behav."},{"issue":"4","key":"10.1016\/j.cct.2025.107954_bb0120","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/nur.4770130405","article-title":"A critical review of visual analogue scales in the measurement of clinical phenomena","volume":"13","author":"Wewers","year":"1990","journal-title":"Res. Nurs. Health"},{"issue":"1","key":"10.1016\/j.cct.2025.107954_bb0125","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/SAR.S38902","article-title":"The treatment effectiveness assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction","volume":"3","author":"Ling","year":"2012","journal-title":"Subst. Abus. Rehabil."},{"issue":"3","key":"10.1016\/j.cct.2025.107954_bb0130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1017\/S0033291700035558","article-title":"The inventory of depressive symptomatology (IDS): psychometric properties","volume":"26","author":"Rush","year":"1996","journal-title":"Psychol. Med."},{"issue":"1\u20132","key":"10.1016\/j.cct.2025.107954_bb0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2015.07.062","article-title":"Development and validation of the dimensional anhedonia rating scale (DARS) in a community sample and individuals with major depression","volume":"229","author":"Rizvi","year":"2015","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.cct.2025.107954_bb0140","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4088\/JCP.11m06837","article-title":"Concise health risk tracking scale: a brief self-report and clinician rating of suicidal risk","volume":"72","author":"Trivedi","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2025.107954_bb0145","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2147\/NDT.S406909","article-title":"Psychometrics of the concise health risk tracking self-report (CHRT-SR(16)) assessment of suicidality in a sample of adults with moderate to severe methamphetamine use disorder: findings from the ADAPT-2 randomized trial","volume":"19","author":"Trombello","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"7","key":"10.1016\/j.cct.2025.107954_bb0150","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","article-title":"Columbia classification algorithm of suicide assessment (C-CASA): classification of suicidal events in the FDA\u2019S pediatric suicidal risk analysis of antidepressants","volume":"164","author":"Posner","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.cct.2025.107954_bb0160","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0277-9536(88)90397-8","article-title":"Disclosure of traumas and psychosomatic processes","volume":"26","author":"Pennebaker","year":"1988","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.cct.2025.107954_bb0165","series-title":"The Life Stressor Checklist-Revised (LSC-R)","author":"Wolfe","year":"1997"},{"key":"10.1016\/j.cct.2025.107954_bb0170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpsychires.2014.08.003","article-title":"Self-rated measure of pain frequency, intensity, and burden: psychometric properties of a new instrument for the assessment of pain","volume":"59","author":"de la Cruz","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.cct.2025.107954_bb0175","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/aje\/kwr193","article-title":"The PhenX toolkit: get the most from your measures","volume":"174","author":"Hamilton","year":"2011","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.cct.2025.107954_bb0180","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1","article-title":"Factor structure of the Barratt impulsiveness scale","volume":"51","author":"Patton","year":"1995","journal-title":"J. Clin. Psychol."},{"issue":"4","key":"10.1016\/j.cct.2025.107954_bb0185","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.biopsych.2004.11.026","article-title":"Toward an objective characterization of an anhedonic phenotype: a signal-detection approach","volume":"57","author":"Pizzagalli","year":"2005","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2025.107954_bb0190","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1192\/bjp.167.1.99","article-title":"A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale","volume":"167","author":"Snaith","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.cct.2025.107954_bb0195","series-title":"Iowa Gambling Task Professional Manual","author":"Bechara","year":"2007"},{"issue":"3","key":"10.1016\/j.cct.2025.107954_bb0200","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1176\/appi.ajp.2019.18080911","article-title":"An electroencephalography connectomic profile of posttraumatic stress disorder","volume":"177","author":"Toll","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"10173","key":"10.1016\/j.cct.2025.107954_bb0205","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cct.2025.107954_bb0210","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.cct.2025.107954_bb0215","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/01.jcp.0000138766.15858.c6","article-title":"Effects of high-dose intravenous buprenorphine in experienced opioid abusers","volume":"24","author":"Umbricht","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.cct.2025.107954_bb0220","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/add.13753","article-title":"Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot\/feasibility randomized trial","volume":"112","author":"Korthuis","year":"2017","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.cct.2025.107954_bb0225","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.cct.2025.107954_bb0230","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1530-0277.2007.00593.x","article-title":"Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics","volume":"32","author":"Lucey","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.cct.2025.107954_bb0235","series-title":"Estimates of Drug Overdose Deaths Involving Fentanyl, Methamphetamine, Cocaine, Heroin, and Oxycodone: United States, 2021, Vital Statistics Rapid Release","author":"MR","year":"2023"},{"key":"10.1016\/j.cct.2025.107954_bb0240","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2020 National Survey on Drug Use and Health Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration Rockville MD, 2021."},{"key":"10.1016\/j.cct.2025.107954_bb0245","article-title":"Antidepressants for cocaine dependence and problematic cocaine use","volume":"12","author":"Pani","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.cct.2025.107954_bb0250","doi-asserted-by":"crossref","first-page":"e1169","DOI":"10.4088\/JCP.13r08525","article-title":"Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials","volume":"74","author":"Kishi","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.cct.2025.107954_bb0255","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jsat.2009.07.001","article-title":"Anticonvulsant drugs in cocaine dependence: a systematic review and meta-analysis","volume":"38","author":"Alvarez","year":"2010","journal-title":"J. Subst. Abus. Treat."},{"issue":"7","key":"10.1016\/j.cct.2025.107954_bb0260","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4088\/JCP.13m08862","article-title":"Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence","volume":"75","author":"Winhusen","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.cct.2025.107954_bb0265","article-title":"Psychostimulant drugs for cocaine dependence","volume":"9","author":"Castells","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cct.2025.107954_bb0270","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003352.pub3","article-title":"Dopamine agonists for the treatment of cocaine dependence","volume":"12","author":"Amato","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl. 20","key":"10.1016\/j.cct.2025.107954_bb0275","first-page":"22","article-title":"The Mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.cct.2025.107954_bb0280","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4088\/JCP.11m06840","article-title":"Concise associated symptoms tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality","volume":"72","author":"Trivedi","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.cct.2025.107954_bb0285","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.cct.2025.107954_bb0290","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2017.03.022","article-title":"Development and validation of a brief assessment of recovery capital (BARC-10) for alcohol and drug use disorder","volume":"177","author":"Vilsaint","year":"2017","journal-title":"Drug Alcohol Depend."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171442500148X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171442500148X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:11:06Z","timestamp":1749035466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155171442500148X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":57,"alternative-id":["S155171442500148X"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.107954","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized, placebo-controlled trial of injectable extended-release naltrexone and injectable extended-release buprenorphine for cocaine use disorder (CURB-2): Study rationale and design","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.107954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107954"}}